Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial

This open-label RCT (n=200) found recombinant human granulocyte colony-stimulating factor (5 mcg/kg days 0-2) did not shorten time to clinical improvement (median of 12 days v 13 days with usual care; HR 1.28; 95% CI 0.95-1.71; P=0.06).

SPS commentary:

The proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock (2% vs 15% with usual care) and rate of death at 21 days (2% v 10%) were lower in the recombinant human granulocyte colony-stimulating factor group, but these were secondary endpoints. Larger studies including a broader range of patients with COVID-19 are required.

JAMA Internal Medicine

Resource links:

Commentary